- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02240134
Wood Stove Interventions and Child Respiratory Health (KidsAIR)
Wood Stove Interventions and Child Respiratory Infections in Rural Communities
Study Overview
Status
Conditions
Detailed Description
Rural and Native areas of the western United States (US) and Alaska experience substantial exposure and health disparities compared to more populated urban centers. One such source of disparity is the elevated inhalation exposures related to the use of wood stoves for home heating. Within rural areas of Montana, Alaska, and the Navajo Nation, research has shown that residential biomass combustion leads to indoor levels of fine particulate matter (PM2.5) that often exceed current health-based air quality standards. Parallel findings have been observed in several developing countries where biomass combustion is commonly used for cooking and/or heating. This is concerning, as PM2.5 exposure is associated with many adverse health outcomes, including a greater than three-fold increased risk of acute respiratory tract infections. Throughout the world, lower respiratory tract infections (LRTIs) are the most common cause of death in children under five years of age, and account for more than 27% of all hospitalizations among US children under five years. Importantly, untoward effects of recurrent LRTIs are cumulative in children and a recognized risk factor for asthma.
Currently, there is a global effort to reduce indoor biomass smoke exposures in developing countries. A recent intervention trial found that exposure reductions following the introduction of improved cookstoves was protective for severe infant pneumonia. Similar evidence-based efforts are warranted in rural and Native American communities in the US that suffer from elevated rates of childhood LRTI and commonly use wood for residential heating. The investigators have previously demonstrated that a community-wide wood stove changeout program (i.e., replacing old wood stoves with newer model wood stoves) resulted in reduced wintertime ambient PM2.5 and corresponding reductions in occurrence of childhood wheeze and respiratory infections. In this and other studies, however, inconsistent effects on indoor air quality following the introduction of newer technology wood stoves have been observed. The investigators have also shown that the introduction of air filtration units is a less costly and more efficacious strategy for reducing indoor wood smoke exposures. Nevertheless, the energy costs of operation and need for filter replacement (maintenance) remain barriers to widespread dissemination and continued compliance in rural and economically disadvantaged communities. Experience with these interventions and qualitative input from wood stove experts suggest that educational interventions related to wood stove operation can translate to low-cost and sustainable strategies that reduce indoor biomass combustion exposures and improve respiratory health.
In this project, the investigators propose to test the efficacy of an education-based intervention strategy for reducing indoor wood smoke exposures and children's risk of LRTI in three unique and underserved settings. This study is a three-arm randomized trial in wood stove homes with children less than five years old. Education on best-burn practices and training on the use of simple instruments (i.e., stove thermometers and wood moisture meters) will be introduced as one intervention arm (Tx1). This intervention will be evaluated against an indoor air filtration unit arm (Tx2), as well as a placebo arm (Tx3, sham air filters). The primary outcome will be LRTI incidence among children under five years of age. A sample of 324 homes, or 108 within each study area equally assigned to each of the three intervention arms, will allow for detection of exposure and outcome differences within each of the three regions. Through three Aims, the overall hypothesis is that a low-cost, educational intervention targeting indoor wood smoke (PM2.5) exposures will be an effective, sustainable strategy for reducing children's risk of LRTI in underserved Native and rural communities.
Aim 1: Compare LRTI incidence in each intervention arm (Tx1 and Tx2) to LRTI in the placebo arm (Tx3). Investigators hypothesize that children less than five years old in intervention homes will experience lower LRTI.
Aim 2: Compare indoor PM2.5 concentrations in each treatment arm relative to the placebo arm. Investigators hypothesize that the intervention homes will have lower indoor PM2.5 concentrations.
Aim 3: Compare effectiveness and sustainability of treatment strategies relative to placebo, both within and between regional sites. Investigators hypothesize that Tx1 will be more effective and sustainable than Tx2.
Impact. LRTI is an important cause of morbidity among children, and exposure to biomass smoke puts children at a greater risk of LRTI. By reducing in-home wood smoke exposures, this study will evaluate sustainable evidence-based and culturally appropriate strategies for decreasing occurrence of LRTI. In addition, comparing the effectiveness of these interventions across three unique rural and Native regions will inform translation of study findings into diverse settings that utilize biomass fuels for heating and cooking.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Montana
-
Missoula, Montana, United States, 59812
- University of Montana
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Eligible homes will be any home in the described communities that uses a wood stove as a primary heating source, and has one or more children under the age of five years. The home must include a parent who is capable and willing to record symptom data for the enrolled children and wood stove usage data.
Exclusion Criteria:
- None.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Education Intervention (Tx1)
The education components for this intervention are based on recent observations and recommendations from tribal, local, state and federal agencies.
The intervention will be a combination of a strong education campaign coupled with the distribution of inexpensive tools to the homes that will enable the residents to burn wood more efficiently.
|
The intervention will be a combination of a strong education campaign coupled with the distribution of inexpensive tools to the homes that will enable the residents to burn wood more efficiently.
|
|
Active Comparator: Air Filtration Unit Treatment (Tx2)
Within each randomly assigned home, a 20" x 18" Filtrete air filtration unit (Ultra Clean Air Purifiers, 3M, St. Paul, MN) will be placed in the same room as the wood stove.
|
A 20" x 18" Filtrete air filtration unit (Ultra Clean Air Purifiers, 3M, St. Paul, MN) will be placed in the same room as the wood stove.
These units are rated by their ability to provide an equivalent amount of contaminant free air into the space, and have a smoke Clean Air Delivery Rate of 112.
The electrostatically charged filters in these units are approximately 85% efficient at removing 0.2 micron particles (cigarette smoke size particles) and over 95% efficient at removing 3 micron particles.
The unit will be operated on the "high" setting throughout the duration of the six-month assessment winter periods.
Filters will be changed out by the Community Coordinator approximately once per month in an effort to maximize collection efficiency.
|
|
Sham Comparator: Placebo Intervention (Tx3)
Similar to Tx1, a 20" x 18" Filtrete air filtration unit will be installed within the wood stove home.
Instead of a high efficiency filter, the units will utilize a placebo filter.
|
Similar to Tx1, a 20" x 18" Filtrete air filtration unit will be installed within the wood stove home.
Instead of a high efficiency filter, the units will utilize a placebo filter.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With at Least One LRTI During Follow-up Period
Time Frame: The participants will be followed for four months during each of two successive winter periods for a total of eight months of observation.
|
The occurrence and duration of LRTI among children will be assessed using active surveillance within the home.
Identification of LRTI episodes will occur through a three step process: (1) parent reporting of symptoms; (2) Community Coordinator collection of confirmatory and severity data; and (3) physician classification of case status based on data collected by the Community Coordinator, and when available, data collected from a clinic or hospital.
|
The participants will be followed for four months during each of two successive winter periods for a total of eight months of observation.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fine Particulate Matter Concentrations
Time Frame: Six consecutive days during a four month winter period
|
Fine particulate matter (PM2.5)
concentrations by study arm
|
Six consecutive days during a four month winter period
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Curtis W Noonan, Ph.D., University of Montana
- Principal Investigator: Tony J Ward, Ph.D., University of Montana
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB 276-13
- R01ES022649 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lower Tract Respiratory Infection
-
Ankara Etlik City HospitalCompletedLower Respiratory Tract InfectionTurkey (Türkiye)
-
Laboratorio Farmaceutico SIT srlRecruitingRespiratory Infection | Lower Respiratory Tract Infection (LRTI)Italy, North Macedonia
-
Qingtao ZhouCompleted
-
Hadassah Medical OrganizationUnknown
-
Bin CaoBioMérieuxUnknown
-
Dr Boillat-Blanco NoemieUniversity Hospital, Basel, Switzerland; Luzerner Kantonsspital; Cantonal Hospital... and other collaboratorsCompletedProcalcitonin and Lung Ultrasonography Guided Antibiotherapy in Emergency Departments (PLUS-IS-LESS)Lower Respiratory Tract InfectionSwitzerland
-
Yale UniversityNational Institute on Aging (NIA)CompletedPneumonia | Lower Respiratory Tract InfectionUnited States
-
John HaleRecruitingLower Respiratory Tract Infection | Upper Respiratory Tract InfectionNew Zealand
-
ADMA Biologics, Inc.CompletedLower Respiratory Tract Infection | Upper Respiratory Tract InfectionUnited States, Canada
-
Fundacio d'Investigacio en Atencio Primaria Jordi...Not yet recruitingLower Respiratory Tract Infection | Primary Health Care
Clinical Trials on Education Intervention (Tx1)
-
University of MontanaNational Institute of Environmental Health Sciences (NIEHS)CompletedRespiratory Infection Other | Respiratory; Disorder, Functional, ImpairedUnited States
-
Ohio State University Comprehensive Cancer CenterCompletedMalignant Solid Neoplasm | Hematopoietic and Lymphoid System NeoplasmUnited States
-
Roswell Park Cancer InstituteCompleted
-
University of WashingtonNational Cancer Institute (NCI)CompletedAdvanced Malignant NeoplasmUnited States
-
Ohio State University Comprehensive Cancer CenterCompletedMalignant Solid Neoplasm | Hematopoietic and Lymphatic System NeoplasmUnited States
-
Fred Hutchinson Cancer CenterPrevent Cancer FoundationCompleted
-
M.D. Anderson Cancer CenterWithdrawnStage IB3 Cervical Cancer FIGO 2018 | Stage II Cervical Cancer FIGO 2018 | Stage IIA Cervical Cancer FIGO 2018 | Stage IIA1 Cervical Cancer FIGO 2018 | Stage IIA2 Cervical Cancer FIGO 2018 | Stage IIB Cervical Cancer FIGO 2018 | Stage III Cervical Cancer FIGO 2018 | Stage IIIA Cervical Cancer FIGO... and other conditions
-
Mayo ClinicTerminated
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityTerminatedMalignant NeoplasmUnited States
-
Ohio State University Comprehensive Cancer CenterCompleted